Company Overview and News

0
Actinogen Medical presenting successes with Xanamem at BIO International

2018-05-31 proactiveinvestors.com.au
Actinogen Medical Ltd (ASX:ACW) CEO and managing director Dr. Bill Ketelbey speaks to Proactive Investors about progress with its promising cortisol inhibitor, Xanamem.
AEF ACW AHCLF

0
Actinogen Medical attracts $15 million to progress Alzheimer’s disease therapy

2018-05-23 proactiveinvestors.com.au
Actinogen Medical Ltd (ASX:ACW) has successfully raised $15 million through an institutional placement at a price of 5 cents per share.
AEF ACW AHCLF

12
Spin-off with benefits: Wesfarmers without Coles may attract ethical funds

2018-04-11 theage.com.au
Wesfarmers is set to become more attractive to ethical investors without the baggage of Coles and coal. It's a different story for the stand-alone supermarket chain.
MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA AEF AHCLF

12
Spin-off with benefits: Wesfarmers without Coles may attract ethical funds

2018-04-11 smh.com.au
Wesfarmers is set to become more attractive to ethical investors without the baggage of Coles and coal. It's a different story for the stand-alone supermarket chain.
MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA AEF AHCLF

5
Antisense Therapeutics raising $5+ million for muscle-wasting disease trials

2018-04-06 proactiveinvestors.com.au
Antisense Therapeutics Limited (ASX:ANP) has successfully completed a share placement to Australian Ethical Investment to raise $581,614 at 2.4 cents each.
ATHJY IONS ANP AEF ATHJF AHCLF

0
Immutep Ltd raises $6.8 million to fund immuno-oncology clinical development program

2018-03-11 proactiveinvestors.com.au
Immutep Ltd (ASX:IMM) has raised about $6.8 million through the placement of more than 326 million new fully paid ordinary shares at an issue price of 2.1 cents.
PTM AEF AHCLF

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to ASX:AEF / AUSTRALIAN ETHICAL INVESTMENT LIMITED on message board site Silicon Investor.

Bernie Schaefferu0027s - Option program